Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications
European Journal of Haematology · 2024
DOI: 10.1111/ejh.14181 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Antonella Bruzzese und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Onco-hematology, Hematology Unit, A.O. of Cosenza, Cosenza, Italy. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Chromosome Deletion, Chromosomes, Human, Pair 5. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 77 Literaturangaben.
Abstract (Originalsprache)
Myelodysplastic syndromes (MDS) encompass a heterogeneous set of acquired bone marrow neoplastic disorders characterized by ineffective hematopoiesis within one or more bone marrow lineages. Nearly half of MDS patients carry cytogenetic alterations, with del(5q) being the most prevalent. Since its first description, del(5q) was consistently correlated with a typical clinical phenotype marked by anemia, thrombocytosis, and a low risk of evolving into acute leukemia. Presently, the World Health Organization (WHO) classification of myeloid neoplasms recognizes a specific subtype of MDS known as “myelodysplastic neoplasm with low blast and isolated del(5q)” identified by the sole presence of 5q deletion or in combination with one other abnormality excluding −7/del(7q). Several studies have sought to unravel the biological processes triggered by del(5q) in the development of MDS, revealing the involvement of various genes localized in specific regions of chromosome 5 referred to as common deleted regions (CDR). This intricate biological landscape makes the MDS cells with del(5q) exceptionally sensitive to lenalidomide. Several studies have confirmed the efficacy of lenalidomide in this context. Regrettably, the response to lenalidomide is not conclusive, prompting ongoing research into biological mechanisms that drive patients toward leukemia and strategies to circumvent lenalidomide resistance and disease progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Onco-hematology, Hematology Unit, A.O. of Cosenza, Cosenza, Italy.
- SOC Ematologia Azienda USL-IRCSS di Reggio Emilia, Reggio Emilia, Italy.
- Scientific Direction Azienda USL-IRCCS of Reggio Emilia, Reggio Emilia, Italy.
- Biotechnology Research Unit, Aprigliano, A.O./ASP of Cosenza, Cosenza, Italy.
- Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.
ORCID-Profile: Antonella Bruzzese, Enrica Antonia Martino, Francesco Mendicino, Isabella Capodanno, Antonino Neri, Fortunato Morabito, Massimo Gentile
Zitieren
APA
Bruzzese, A., Martino, E. A., Mendicino, F., Lucia, E., Olivito, V., Capodanno, I., Neri, A., Morabito, F., Vigna, E., & Gentile, M. (2024). Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications. European Journal of Haematology. https://doi.org/10.1111/ejh.14181
Vancouver
Bruzzese A, Martino EA, Mendicino F, Lucia E, Olivito V, Capodanno I, et al. Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications. European Journal of Haematology. 2024. doi:10.1111/ejh.14181
BibTeX
@article{Bruzzese2024,
author = {Bruzzese, Antonella and Martino, Enrica Antonia and Mendicino, Francesco and Lucia, Eugenio and Olivito, Virginia and Capodanno, Isabella and Neri, Antonino and Morabito, Fortunato and Vigna, Ernesto and Gentile, Massimo},
title = {Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications},
journal = {European Journal of Haematology},
year = {2024},
doi = {10.1111/ejh.14181}
}
EUVIMED